These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 31330805)

  • 1. Etelcalcetide in Patients on Hemodialysis with Severe Secondary Hyperparathyroidism. Multicenter Study in "Real Life".
    Russo D; Tripepi R; Malberti F; Di Iorio B; Scognamiglio B; Di Lullo L; Paduano IG; Tripepi GL; Panuccio VA
    J Clin Med; 2019 Jul; 8(7):. PubMed ID: 31330805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved Control of Secondary Hyperparathyroidism in Hemodialysis Patients Switching from Oral Cinacalcet to Intravenous Etelcalcetide, Especially in Nonadherent Patients.
    Xipell M; Montagud-Marrahi E; Rubio MV; Ojeda R; Arias-Guillén M; Fontseré N; Rodas L; Vera M; Broseta JJ; Torregrosa V; Filella X; Maduell F
    Blood Purif; 2019; 48(2):106-114. PubMed ID: 30699421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Experience of Using Etelcalcetide for Secondary Hyperparathyroidism in Community-Based Hemodialysis Centers in Singapore.
    Khan BA; Qu X; Hua Y; Javaid MM
    Cureus; 2023 Nov; 15(11):e48186. PubMed ID: 38050530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial.
    Block GA; Bushinsky DA; Cheng S; Cunningham J; Dehmel B; Drueke TB; Ketteler M; Kewalramani R; Martin KJ; Moe SM; Patel UD; Silver J; Sun Y; Wang H; Chertow GM
    JAMA; 2017 Jan; 317(2):156-164. PubMed ID: 28097356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term effects of etelcalcetide as intravenous calcimimetic therapy in hemodialysis patients with secondary hyperparathyroidism.
    Shigematsu T; Fukagawa M; Yokoyama K; Akiba T; Fujii A; Odani M; Akizawa T;
    Clin Exp Nephrol; 2018 Apr; 22(2):426-436. PubMed ID: 28836058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A case of a hemodialysis patient with secondary hyperparathyroidism who was resistant to etelcalcetide treatment but not to cinacalcet hydrochloride.
    Nakamura H; Tokumoto M; Anayama M; Kurihara S; Makino Y; Tamura K; Nagasawa M
    CEN Case Rep; 2022 May; 11(2):254-258. PubMed ID: 34787825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of etelcalcetide in the management of secondary hyperparathyroidism in hemodialysis patients: a review on current data and place in therapy.
    Friedl C; Zitt E
    Drug Des Devel Ther; 2018; 12():1589-1598. PubMed ID: 29910605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Managing hyperparathyroidism in hemodialysis: role of etelcalcetide.
    Eidman KE; Wetmore JB
    Int J Nephrol Renovasc Dis; 2018; 11():69-80. PubMed ID: 29440923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An integrated analysis of safety and tolerability of etelcalcetide in patients receiving hemodialysis with secondary hyperparathyroidism.
    Block GA; Chertow GM; Sullivan JT; Deng H; Mather O; Tomlin H; Serenko M
    PLoS One; 2019; 14(3):e0213774. PubMed ID: 30875390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Etelcalcetide Versus Cinacalcet in Hemodialysis Patients in the United States: A Facility Calcimimetic Approach to Assess Real-World Effectiveness.
    Karaboyas A; Muenz D; Hwang Y; Goodman W; Cheng S; Desai P; Fox KM; Robinson BM; Pisoni RL
    Kidney Med; 2022 Jun; 4(6):100475. PubMed ID: 35637925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of secondary hyperparathyroidism in patients on hemodialysis using a novel synthetic peptide calcimimetic, etelcalcetide: a short-term clinical study.
    Mima A; Tansho K; Nagahara D; Watase K
    J Int Med Res; 2018 Nov; 46(11):4578-4585. PubMed ID: 30027791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Etelcalcetide versus placebo for secondary hyperparathyroidism in patients receiving hemodialysis: A meta-analysis of randomized controlled trials.
    Zhu Y; Ou J; Liu X; Xie Z
    Clin Nephrol; 2020 Oct; 94(4):173-180. PubMed ID: 32729818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Effectiveness of Calcimimetic Agents for Secondary Hyperparathyroidism in Adults: A Systematic Review and Network Meta-analysis.
    Palmer SC; Mavridis D; Johnson DW; Tonelli M; Ruospo M; Strippoli GFM
    Am J Kidney Dis; 2020 Sep; 76(3):321-330. PubMed ID: 32475604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Long-term efficacy and safety of etelcalcetide in hemodialysis patients with severe secondary hyperparathyroidism].
    Massimetti C; Tondo M; Feriozzi S
    G Ital Nefrol; 2020 Oct; 37(5):. PubMed ID: 33026204
    [No Abstract]   [Full Text] [Related]  

  • 15. Etelcalcetide Utilization, Dosing Titration, and Chronic Kidney Disease-Mineral and Bone Disease (CKD-MBD) Marker Responses in US Hemodialysis Patients.
    Karaboyas A; Muenz D; Fuller DS; Desai P; Lin TC; Robinson BM; Rossetti S; Pisoni RL
    Am J Kidney Dis; 2022 Mar; 79(3):362-373. PubMed ID: 34273436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of etelcalcetide, an intravenous calcimimetic, for up to 52 weeks in hemodialysis patients with secondary hyperparathyroidism: results of a post-marketing surveillance in Japan.
    Yokoyama K; Fukagawa M; Shigematsu T; Akiba T; Yoshikawa K; Tsuchiya A; Kuwabara M; Akizawa T
    Clin Exp Nephrol; 2021 Jan; 25(1):66-79. PubMed ID: 32816132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemodialysis patients.
    Fukagawa M; Yokoyama K; Shigematsu T; Akiba T; Fujii A; Kuramoto T; Odani M; Akizawa T;
    Nephrol Dial Transplant; 2017 Oct; 32(10):1723-1730. PubMed ID: 28057872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism.
    Bushinsky DA; Chertow GM; Cheng S; Deng H; Kopyt N; Martin KJ; Rastogi A; Ureña-Torres P; Vervloet M; Block GA
    Nephrol Dial Transplant; 2020 Oct; 35(10):1769-1778. PubMed ID: 30859218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current therapeutic options for the treatment of secondary hyperparathyroidism in end-stage renal disease patients treated with hemodialysis: a 12-month comparative study.
    Dudar I; Shifris I; Dudar S; Kulish V
    Pol Merkur Lekarski; 2022 Oct; 50(299):294-298. PubMed ID: 36283011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of active vitamin D analogs and calcimimetic agents on PTH and bone mineral biomarkers in hemodialysis patients with SHPT: a network meta-analysis.
    Liu X; Liu Y; Zheng P; Xie X; Li Z; Yang R; Jin L; Mei Z; Chen P; Zhou L
    Eur J Clin Pharmacol; 2024 Jul; ():. PubMed ID: 39002024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.